133 related articles for article (PubMed ID: 18722529)
1. Entacapone potentiates the long-duration response but does not normalize levodopa-induced molecular changes.
Marin C; Aguilar E; Mengod G; Cortés R; Rodríguez-Oroz MC; Obeso JA
Neurobiol Dis; 2008 Dec; 32(3):340-8. PubMed ID: 18722529
[TBL] [Abstract][Full Text] [Related]
2. Effects of early vs. late initiation of levodopa treatment in hemiparkinsonian rats.
Marin C; Aguilar E; Mengod G; Cortés R; Obeso JA
Eur J Neurosci; 2009 Sep; 30(5):823-32. PubMed ID: 19712101
[TBL] [Abstract][Full Text] [Related]
3. Effect of subthalamic nucleus or entopeduncular nucleus lesion on levodopa-induced neurochemical changes within the basal ganglia and on levodopa-induced motor alterations in 6-hydroxydopamine-lesioned rats.
Périer C; Marin C; Jimenez A; Bonastre M; Tolosa E; Hirsch EC
J Neurochem; 2003 Sep; 86(6):1328-37. PubMed ID: 12950442
[TBL] [Abstract][Full Text] [Related]
4. Entacapone, a catechol-O-methyltransferase inhibitor, improves the motor activity and dopamine content of basal ganglia in a rat model of Parkinson's disease induced by Japanese encephalitis virus.
Hamaue N; Ogata A; Terado M; Tsuchida S; Yabe I; Sasaki H; Hirafuji M; Togashi H; Aoki T
Brain Res; 2010 Jan; 1309():110-5. PubMed ID: 19879254
[TBL] [Abstract][Full Text] [Related]
5. Early L-dopa, but not pramipexole, restores basal ganglia activity in partially 6-OHDA-lesioned rats.
Marin C; Bonastre M; Mengod G; Cortés R; Giralt A; Obeso JA; Schapira AH
Neurobiol Dis; 2014 Apr; 64():36-47. PubMed ID: 24370700
[TBL] [Abstract][Full Text] [Related]
6. Concomitant short- and long-duration response to levodopa in the 6-OHDA-lesioned rat: a behavioural and molecular study.
Marin C; Aguilar E; Mengod G; Cortés R; Obeso JA
Eur J Neurosci; 2007 Jan; 25(1):259-69. PubMed ID: 17241287
[TBL] [Abstract][Full Text] [Related]
7. Effect of repeated L-DOPA, bromocriptine, or lisuride administration on preproenkephalin-A and preproenkephalin-B mRNA levels in the striatum of the 6-hydroxydopamine-lesioned rat.
Henry B; Crossman AR; Brotchie JM
Exp Neurol; 1999 Feb; 155(2):204-20. PubMed ID: 10072296
[TBL] [Abstract][Full Text] [Related]
8. Reversion of levodopa-induced motor fluctuations by the A2A antagonist CSC is associated with an increase in striatal preprodynorphin mRNA expression in 6-OHDA-lesioned rats.
Bové J; Serrats J; Mengod G; Cortés R; Aguilar E; Marin C
Synapse; 2006 Jun; 59(7):435-44. PubMed ID: 16498608
[TBL] [Abstract][Full Text] [Related]
9. Effect of pulsatile administration of levodopa on dyskinesia induction in drug-naïve MPTP-treated common marmosets: effect of dose, frequency of administration, and brain exposure.
Smith LA; Jackson MJ; Hansard MJ; Maratos E; Jenner P
Mov Disord; 2003 May; 18(5):487-95. PubMed ID: 12722161
[TBL] [Abstract][Full Text] [Related]
10. Coadministration of entacapone with levodopa attenuates the severity of dyskinesias in hemiparkinsonian rats.
Marin C; Aguilar E; Obeso JA
Mov Disord; 2006 May; 21(5):646-53. PubMed ID: 16437585
[TBL] [Abstract][Full Text] [Related]
11. Effect of non-dopaminergic drug treatment on Levodopa induced dyskinesias in MPTP monkeys: common implication of striatal neuropeptides.
Tamim MK; Samadi P; Morissette M; Grégoire L; Ouattara B; Lévesque D; Rouillard C; Di Paolo T
Neuropharmacology; 2010 Jan; 58(1):286-96. PubMed ID: 19576910
[TBL] [Abstract][Full Text] [Related]
12. Early administration of entacapone prevents levodopa-induced motor fluctuations in hemiparkinsonian rats.
Marin C; Aguilar E; Bonastre M; Tolosa E; Obeso JA
Exp Neurol; 2005 Mar; 192(1):184-93. PubMed ID: 15698633
[TBL] [Abstract][Full Text] [Related]
13. Behavioral and biochemical correlates of the dyskinetic potential of dopaminergic agonists in the 6-OHDA lesioned rat.
Carta AR; Frau L; Pinna A; Pontis S; Simola N; Schintu N; Morelli M
Synapse; 2008 Jul; 62(7):524-33. PubMed ID: 18435422
[TBL] [Abstract][Full Text] [Related]
14. Unilateral 6-hydroxydopamine lesion of dopamine neurons and subchronic L-DOPA administration in the adult rat alters the expression of the vesicular GABA transporter in different subsets of striatal neurons and in the substantia nigra, pars reticulata.
Wang H; Katz J; Dagostino P; Soghomonian JJ
Neuroscience; 2007 Mar; 145(2):727-37. PubMed ID: 17218060
[TBL] [Abstract][Full Text] [Related]
15. Subthalamic 6-OHDA-induced lesion attenuates levodopa-induced dyskinesias in the rat model of Parkinson's disease.
Marin C; Bonastre M; Mengod G; Cortés R; Rodríguez-Oroz MC; Obeso JA
Exp Neurol; 2013 Dec; 250():304-12. PubMed ID: 24140562
[TBL] [Abstract][Full Text] [Related]
16. Chronic high dose L-DOPA alone or in combination with the COMT inhibitor entacapone does not increase oxidative damage or impair the function of the nigro-striatal pathway in normal cynomologus monkeys.
Lyras L; Zeng BY; McKenzie G; Pearce RK; Halliwell B; Jenner P
J Neural Transm (Vienna); 2002; 109(1):53-67. PubMed ID: 11793162
[TBL] [Abstract][Full Text] [Related]
17. LY293558, an AMPA glutamate receptor antagonist, prevents and reverses levodopa-induced motor alterations in Parkinsonian rats.
Marin C; Jiménez A; Bonastre M; Vila M; Agid Y; Hirsch EC; Tolosa E
Synapse; 2001 Oct; 42(1):40-7. PubMed ID: 11668589
[TBL] [Abstract][Full Text] [Related]
18. MK-801 alters the effects of priming with L-DOPA on dopamine D1 receptor-induced changes in neuropeptide mRNA levels in the rat striatal output neurons.
Van De Witte SV; Groenewegen HJ; Voorn P
Synapse; 2002 Jan; 43(1):1-11. PubMed ID: 11746728
[TBL] [Abstract][Full Text] [Related]
19. Differential expression of striatal synaptotagmin mRNA isoforms in hemiparkinsonian rats.
Glavan G; Zivin M
Neuroscience; 2005; 135(2):545-54. PubMed ID: 16111820
[TBL] [Abstract][Full Text] [Related]
20. Intermittent L-DOPA treatment differentially alters synaptotagmin 4 and 7 gene expression in the striatum of hemiparkinsonian rats.
Glavan G
Brain Res; 2008 Oct; 1236():216-24. PubMed ID: 18721798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
